Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02465983 · ClinicalTrials.gov registry record · Phase 1
Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
A Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02465983: Clinical Trial Phase 1 study, sponsored by University of Pennsylvania.
NCT02465983 is a Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02465983, a Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a study in which pancreatic cancer patients receive a combination therapy with CART-meso cells and CART19 cells administered at 3 days after one dose of cyclophosphamide. CART-meso cells are patients' own T cells that were modified in the laboratory to express a receptor specific to the mesothelin protein. CART19 cells are patients' own T cells that were modified in the laboratory to express a receptor specific to a protein called CD19. The CD19 protein is expressed on white blood B cells. CART19 cells are expected to attack the B cells and impede the antibody response against CART-meso cells. The investigators hypothesize that this combination therapy may prolong the duration of CART-meso cells in the body. Additionally, one dose of cyclophosphamide may enhance engraftment and persistence of CART cells.
Interventions
- DRUG Cyclophosphamide
- BIOLOGICAL CART-meso-19 T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-05 |
| Est. Completion | 2017-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02465983
The ClinicalTrials.gov registry entry for NCT02465983 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cyclophosphamide is the first listed.
NCT02465983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02465983 about?
NCT02465983 is a clinical study titled "Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer". This is a study in which pancreatic cancer patients receive a combination therapy with CART-meso cells and CART19 cells administered at 3 days after one dose of cyclophosphamide. CART-meso cells are patients' own T cells that were modified in the laboratory to express a receptor specific to the meso...
What is the current status of trial NCT02465983?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2015-05. Estimated completion is 2017-11.
What interventions are being tested in trial NCT02465983?
The interventions under investigation include: Cyclophosphamide (DRUG), CART-meso-19 T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT02465983?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.